Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Epidemiological studies and cardiovascular prevention trials have shown that low-dose aspirin can reduce colorectal cancer (CRC) incidence and mortality, including inhibition of distant metastases. Metformin has also been associated with decreased colon adenoma recurrence in clinical trials and lower CRC incidence and mortality in epidemiological studies in diabetics. While both drugs have been tested as single agents, their combination has not been tested in cancer prevention trials.
Methods/design: This is a randomized, placebo-controlled, double-blind, 2 × 2 biomarker trial of aspirin and metformin to test the activity of either agent alone and the potential synergism of their combination on a set of surrogate biomarkers of colorectal carcinogenesis. After surgery, 160 patients with stage I-III CRC are randomly assigned in a four-arm trial to either aspirin (100 mg day), metformin (850 mg bis in die), their combination, or placebo for one year. The primary endpoint biomarker is the change of IHC expression of nuclear factor kappa-B (NFκB) in the unaffected mucosa of proximal and distal colon obtained by multiple biopsies in two paired colonoscopies one year apart. Additional biomarkers will include: 1) the measurement of circulating IL-6, CRP and VEGF; 2) the IHC expression of tissue pS6K, p53, beta-catenin, PI3K; 3) the associations of genetic markers with treatment response as assessed by next generation sequencing of primary tumors; 4) the genomic profile of candidate genes, pathways, and overall genomic patterns in tissue biopsies by genome wide gene expression arrays; and 5) the evaluation of adenoma occurrence at 1 year.
Discussion: A favorable biomarker modulation by aspirin and metformin may provide important clues for a subsequent phase III adjuvant trial aimed at preventing second primary cancer, delaying recurrence and improving prognosis in patients with CRC.
Trial Registration: EudraCT Number: 2015-004824-77; ClinicalTrial.gov Identifier: NCT03047837 . Registered on February 1, 2017.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280542 | PMC |
| http://dx.doi.org/10.1186/s12885-018-5126-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Senotherapeutics: Milestones, innovations, and future prospects.
Adv Pharmacol
July 2025
Department of Medical Biochemistry, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, İstanbul, Türkiye. Electronic address:
Gerontological practice has evolved over the decades in response to various diseases, comorbidities, and demographic factors. The many subfields that have emerged from our advancement include the study of biomedical gerontology. Geropharmacology, which began to be recognized as a distinct subfield in the latter part of the 20th century, is the study of how the elderly population responds to pharmaceutical interventions, considering the effects, interactions, and side effects, along with appropriate dosages and routes.
View Article and Find Full Text PDFUnlocking the therapeutic potential of Catharanthus roseus leaves via in-vitro, in-vivo, and in-silico study.
Sci Rep
July 2025
Department of Pharmacy, ASA University Bangladesh, Dhaka-1207, Bangladesh.
Catharanthus roseus (L.) (CR), is a perennial flowering herb, has traditionally been used by local populations in South Asia, Africa, China and Malaysia to treat diabetes, cancer and microbial infection. The principal objective of this study was to investigate the antidiabetic, antilipidemic and antiarthritic effects of methanol (MCR) and ethanol (ECR) extracts and dichloromethane fraction (DCR) of Catharanthus roseus leaves by in-vitro, in-vivo, and in-silico model.
View Article and Find Full Text PDFMetformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.
Lancet Oncol
August 2025
Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie Hospital NHS Foundation Trust, Manchester, UK; Department of Urology, Salford Royal Hospital, Manchester, UK.
Article Synopsis
- Metformin, an anti-diabetic drug, is being studied for its potential anticancer effects, particularly in metastatic hormone-sensitive prostate cancer, where it may also help counteract issues related to androgen-deprivation therapy (ADT).
- The STAMPEDE trial involved patients with high-risk prostate cancer across the UK and Switzerland, comparing standard treatment with and without metformin for non-diabetic patients who were in good health.
- Patients were randomly assigned to receive either standard care or standard care plus metformin, with the main goal of assessing overall survival in those treated with the additional medication.
Chemoprevention of Colorectal Cancer-With Emphasis on Low-Dose Aspirin and Anticoagulants.
Pharmaceuticals (Basel)
May 2025
Faculty of Medicine, Landspitali, University Hospital of Iceland, 101 Reykjavik, Iceland.
Colorectal cancer (CRC) remains the third most common cancer worldwide and a leading cause of cancer-related death. Chemoprevention through widely used pharmaceutical agents has garnered increasing interest due to its potential cost-effectiveness and accessibility. This review summarizes current evidence from observational studies, randomized controlled trials, and meta-analyses on the association between commonly prescribed medications and CRC incidence and survival, with particular emphasis on low-dose aspirin and oral anticoagulants (OACs).
View Article and Find Full Text PDFUpdates on Preeclampsia: Pathogenesis, Biomarkers, Diagnosis, and Management.
Cardiol Rev
June 2025
Division of Nephrology, Department of Medicine, Jacobi Medical Center at Albert Einstein College of Medicine, Bronx, NY.
Preeclampsia complicates 2-4% of pregnancies globally and contributes significantly to maternal and fetal morbidity and mortality. Early-onset preeclampsia (<34 weeks gestation) is primarily characterized by abnormal placentation and defective remodeling of uterine spiral arteries, while late-onset preeclampsia (>34 weeks gestation) often involves a mismatch between normal maternal perfusion and increasing placental metabolic demands. Angiogenic imbalance, featuring elevated antiangiogenic factors [soluble fms-like tyrosine kinase-1 (sFlt-1), soluble endoglin] and decreased proangiogenic factors [placental growth factor (PlGF)], plays a pivotal role in disease manifestation.
View Article and Find Full Text PDF